ClinicalTrials.gg
Status unknownNCT02663024Updated Jan 26, 2016

Study of Idursulfase-beta (GC1111) in Hunter Syndrome

A Phase 2 interventional study of idursulfase beta and idursulfase in Mucopolysaccharidosis II, sponsored by Green Cross Corporation. Status unknown. Open to male participants aged 5 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by Green Cross Corporation · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
5 Years to 35 Years
Sex
Male
01

Study summary

This study evaluates the efficacy and safety of three doses of GC1111 in patients with Hunter Syndrome. Participants will be randomized to one of three doses of GC1111 or comparator.

Read the detailed description

This is a randomized, double-blind, active-controlled, dose-ranging study, where patient will receive one of the three doses of GC1111 (0.5 mg/kg, 1.0 mg/kg, and 1.5 mg/kg) or ELAPRASE 0.5 mg/kg. Approximately 20 patients will be administrated each study drug once every week as an iv infusion for 24 weeks. Efficacy of GC1111 will be evaluated in Six-Minute Walk Test (6MWT), urine Glycosaminoglycans(uGAG), liver and spleen volume, percent predicted Forced Vital Capacity(FVC), and cardiac size and function. Also immunogenicity, Pharmacokinetics(PK) and safety will be evaluated.

02

Conditions studied

  • Mucopolysaccharidosis II
03

In context

Mucopolysaccharidosis II

77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.

This study's planned enrollment of 20 is close to the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.

Browse Mucopolysaccharidosis II studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients between 5 and 35 years of age
  • form signed
  • Patients diagnosed with hunter syndrome
  • Previously untreated with an enzyme replacement therapy

Exclusion criteria

Exclusion Criteria:

  • History of tracheostomy, bone marrow transplant, or cord blood transplant
  • Treatment with another product within 30 days prior to the start of study drug
  • Known of any of the ingredients of study drug
  • Patient with severe hunter syndrome who cannot perform 6MWT
  • Female patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm 1

    0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks

    Biological: idursulfase beta

  • Experimental
    Arm 2

    1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks

    Biological: idursulfase beta

  • Experimental
    Arm 3

    1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks

    Biological: idursulfase beta

  • Active comparator
    Arm 4

    0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks

    Biological: idursulfase

Interventions

  • IV, weekly infusion for 24 weeks

    Also known as: GC1111

  • Biologicalidursulfase

    0.5 mg/kg, iv, weekly infusion for 24 weeks

    Also known as: Elaprase

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in urinary GAG(Glycosaminoglycans) at Week 25

    Time frame: Baseline to Week 25

Secondary outcomes

  1. Change from baseline in urinary GAG at Week 25

    Time frame: Baseline to Week 25

  2. Change from baseline in Six Minute Walk Test at Week 25

    Time frame: Baseline to Week 25

  3. Percent change from baseline in Six Minute Walk Test at Week 25

    Time frame: Baseline to Week 25

  4. Change from baseline in Liver volume at Week 25

    Liver volume measured by MRI

    Time frame: Baseline to Week 25

  5. Percent change from baseline in Liver volume at Week 25

    Liver volume measured by MRI

    Time frame: Baseline to Week 25

  6. Change from baseline in Spleen volume at Week 25

    Spleen volume measured by MRI

    Time frame: Baseline to Week 25

  7. Percent change from baseline in Spleen volume at Week 25

    Spleen volume measured by MRI

    Time frame: Baseline to Week 25

  8. Incidence of Adverse Events and Serious Adverse Events

    Time frame: Baseline to Week 25

  9. Safety changes from baseline in clinical laboratory tests, physical examination and vital signs

    Time frame: Baseline to Week 25

  10. Immunogenicity

    anti-drug-antibody

    Time frame: Baseline to Week 25

  11. Pharmacokinetic profile - Area under the serum concentration time curve (AUClast)

    Time frame: 1 and 17 week

  12. Pharmacokinetic profile - Maximum observed peak plasma concentration (Cmax)

    Time frame: 1 and 17 week

  13. Pharmacokinetic profile - Time at which Cmax is observed (Tmax)

    Time frame: 1 and 17 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Dec 2019 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2016
First posted
Jan 26, 2016
Start
Dec 2016
Primary completionEst.
Dec 2019
CompletionEst.
Jun 2020
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02663024
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Dec 2016
Primary completion
Dec 2019 (estimated)
Completion
Jun 2020 (estimated)
Last update
Jan 26, 2016

Study contacts

Sangmi Kang
Contact
sm6220@greencross.com
82-31-260-1957

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idursulfase beta

Start the discussion